[go: up one dir, main page]

AU2001232735A1 - Process for solubilizing glucagon-like peptide 1 compounds - Google Patents

Process for solubilizing glucagon-like peptide 1 compounds

Info

Publication number
AU2001232735A1
AU2001232735A1 AU2001232735A AU3273501A AU2001232735A1 AU 2001232735 A1 AU2001232735 A1 AU 2001232735A1 AU 2001232735 A AU2001232735 A AU 2001232735A AU 3273501 A AU3273501 A AU 3273501A AU 2001232735 A1 AU2001232735 A1 AU 2001232735A1
Authority
AU
Australia
Prior art keywords
glp
solution
compound
compounds
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001232735A
Inventor
Walter Francis Junior Prouty
Joseph Vincent Junior Rinella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2001232735A1 publication Critical patent/AU2001232735A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Disclosed is a method of preparing a GLP-1 compound that is soluble in aqueous solution at pH 7.4 from a GLP-1 compound that is substantially insoluble in aqueous solution at pH 7.4. The insoluble GLP-1 compound is dissolved in aqueous base or in aqueous acid to form a GLP-1 solution. The GLP-1 solution is then neutralized to a pH at which substantially no amino acid racemization of the GLP-1 compounds occurs, after which the soluble GLP-1 compound is isolated from the neutralized solution.
AU2001232735A 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 compounds Abandoned AU2001232735A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US17843800P 2000-01-27 2000-01-27
US60178438 2000-01-27
US22405800P 2000-08-09 2000-08-09
US60224058 2000-08-09
PCT/US2001/000010 WO2001055213A2 (en) 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 (glp-1) compounds

Publications (1)

Publication Number Publication Date
AU2001232735A1 true AU2001232735A1 (en) 2001-08-07

Family

ID=26874307

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001232735A Abandoned AU2001232735A1 (en) 2000-01-27 2001-01-16 Process for solubilizing glucagon-like peptide 1 compounds

Country Status (17)

Country Link
US (4) US7598222B2 (en)
EP (1) EP1257577B1 (en)
JP (1) JP2003523366A (en)
KR (1) KR20020073184A (en)
AT (1) ATE264870T1 (en)
AU (1) AU2001232735A1 (en)
BR (1) BR0107837A (en)
CA (1) CA2396920A1 (en)
DE (1) DE60102899T2 (en)
DK (1) DK1257577T3 (en)
ES (1) ES2218381T3 (en)
HU (1) HUP0204281A3 (en)
IL (2) IL150913A0 (en)
MX (1) MXPA02007231A (en)
PT (1) PT1257577E (en)
TR (1) TR200401142T4 (en)
WO (1) WO2001055213A2 (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2484966T3 (en) 2000-04-12 2014-08-12 Novozymes Biopharma Dk A/S Albumin fusion proteins
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
EP2277888A3 (en) 2001-12-21 2011-04-27 Human Genome Sciences, Inc. Fusion proteins of albumin and erythropoietin
WO2005003296A2 (en) 2003-01-22 2005-01-13 Human Genome Sciences, Inc. Albumin fusion proteins
WO2003080149A2 (en) 2002-03-20 2003-10-02 Mannkind Corporation Inhalation apparatus
US7550590B2 (en) * 2003-03-25 2009-06-23 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7847063B2 (en) * 2003-03-28 2010-12-07 Sanwa Kagaku Kenkyusho Co., Ltd. GLP-1 derivative
EP1625122A1 (en) 2003-05-14 2006-02-15 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
PL1633391T3 (en) 2003-06-03 2012-03-30 Novo Nordisk As Stabilized pharmaceutical peptide compositions
ATE529126T1 (en) * 2003-06-03 2011-11-15 Novo Nordisk As STABILIZED PHARMACEUTICAL PEPTIDE COMPOSITIONS
JP4936884B2 (en) * 2003-06-03 2012-05-23 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
US20050070531A1 (en) * 2003-08-13 2005-03-31 Syrrx, Inc. Dipeptidyl peptidase inhibitors
JP2007505121A (en) * 2003-09-08 2007-03-08 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
JP2007513058A (en) * 2003-09-08 2007-05-24 武田薬品工業株式会社 Dipeptidyl peptidase inhibitor
CN113304250A (en) * 2003-11-20 2021-08-27 诺和诺德股份有限公司 Propylene glycol-containing peptide formulations optimized for production and use in injection devices
GEP20094679B (en) * 2004-03-15 2009-05-10 Takeda Pharmaceuticals Co Dipeptidyl peptidase inhibitors
PL1786784T3 (en) 2004-08-20 2011-04-29 Mannkind Corp Catalysis of diketopiperazine synthesis
EP1791542B1 (en) 2004-08-23 2015-05-20 Mannkind Corporation Diketopiperazine salts for drug delivery
JP4965446B2 (en) 2004-08-31 2012-07-04 ノヴォ ノルディスク アー／エス Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
JP5175103B2 (en) 2004-11-12 2013-04-03 ノヴォ ノルディスク アー／エス Stable peptide formulation
CN101061144B (en) 2004-11-19 2010-12-29 三井化学株式会社 Ethylene polymer microparticles, functional group-containing ethylene polymer microparticles, and catalyst carrier for production thereof
EP1828192B1 (en) 2004-12-21 2014-12-03 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2006069779A1 (en) * 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
EP1875961B1 (en) 2005-04-07 2018-08-29 Mitsui Chemicals, Inc. Capsular fine particle comprising olefinic polymer
US20070060530A1 (en) 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
EA015735B1 (en) * 2005-09-14 2011-10-31 Такеда Фармасьютикал Компани Лимитед PHARMACEUTICAL COMPOSITIONS BASED ON 2 - [[6 - [(3R) -3-AMINO-1-PIPERIDINIL] -3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1 (2H) -PYRIMIDINYL] METHYL]
US20070060529A1 (en) * 2005-09-14 2007-03-15 Christopher Ronald J Administration of dipeptidyl peptidase inhibitors
KR101643478B1 (en) 2005-09-14 2016-07-27 맨카인드 코포레이션 Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
TW200745080A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of tartrate salt of 2-[2-(3-(R)-amino-piperidin-1-yl)-5-fluoro-6-oxo-6H-pyrimidin-1-ylmethyl]-benzonitrile and methods of use therefor
EP1924567B1 (en) * 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
TW200745079A (en) * 2005-09-16 2007-12-16 Takeda Pharmaceuticals Co Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
BRPI0707599A2 (en) * 2006-02-08 2011-05-10 Lonza Ag glucagon-like peptide synthesis
CA2643464C (en) 2006-02-22 2018-09-04 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
WO2007112347A1 (en) 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
WO2007112368A1 (en) * 2006-03-28 2007-10-04 Takeda Pharmaceutical Company Limited Preparation of (r)-3-aminopiperidine dihydrochloride
US8324383B2 (en) 2006-09-13 2012-12-04 Takeda Pharmaceutical Company Limited Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile
KR102062824B1 (en) * 2006-09-13 2020-01-07 다케다 야쿠힌 고교 가부시키가이샤 Use of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl]-4-fluoro-benzonitrile
TW200838536A (en) * 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US8093236B2 (en) 2007-03-13 2012-01-10 Takeda Pharmaceuticals Company Limited Weekly administration of dipeptidyl peptidase inhibitors
CN106039494B (en) 2008-06-13 2019-12-24 曼金德公司 Dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX336361B (en) 2008-06-20 2015-12-03 Mannkind Corp An interactive apparatus and method for real-time profiling of inhalation efforts.
TWI494123B (en) 2008-08-11 2015-08-01 Mannkind Corp Ultra-fast use of insulin
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2853268A1 (en) 2009-01-08 2015-04-01 Mannkind Corporation Treatment of hyperglycemia with GLP-1
DK2405963T3 (en) 2009-03-11 2013-12-16 Mannkind Corp DEVICE, SYSTEM AND PROCEDURE FOR MEASURING RESISTANCE IN AN INHALATOR
US8551528B2 (en) 2009-06-12 2013-10-08 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011017554A2 (en) * 2009-08-07 2011-02-10 Mannkind Corporation Val (8) glp-1 composition and method for treating functional dyspepsia and/or irritable bowel syndrome
US9016147B2 (en) 2009-11-03 2015-04-28 Mannkind Corporation Apparatus and method for simulating inhalation efforts
EP2582421A1 (en) 2010-06-21 2013-04-24 MannKind Corporation Dry powder drug delivery system and methods
CN102718858B (en) * 2011-03-29 2014-07-02 天津药物研究院 Glucagon-like peptide-1 (GLP-1) analogue monomer and dimer, preparation method therefor and application thereof
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
JP6018640B2 (en) 2011-10-24 2016-11-02 マンカインド コーポレイション Analgesic composition effective for alleviating pain, and dry powder and dry powder drug delivery system comprising the composition
ES2624294T3 (en) 2012-07-12 2017-07-13 Mannkind Corporation Dry powder drug delivery systems
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
CN105102427B (en) 2013-03-21 2018-09-07 赛诺菲-安万特德国有限公司 Synthesis of Peptide Products Containing Cyclic Imides
ES2623979T3 (en) 2013-03-21 2017-07-12 Sanofi-Aventis Deutschland Gmbh Synthesis of peptide products containing hydantoin
AU2014290438B2 (en) 2013-07-18 2019-11-07 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US9969769B2 (en) 2014-12-19 2018-05-15 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
US10308677B2 (en) 2014-12-19 2019-06-04 Cem Corporation Coupling method for peptide synthesis at elevated temperatures
UA127495C2 (en) 2015-12-23 2023-09-13 Амджен Інк. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (en) 2017-01-17 2019-07-16 Amgen Inc Method of treating or ameliorating metabolic disorders using glp-1 receptor agonists conjugated to antagonists for gastric inhibitory peptide receptor (gipr)
MA49460A (en) 2017-06-20 2020-04-29 Amgen Inc METHOD OF TREATMENT OR REDUCTION OF METABOLIC DISORDERS USING GASTRIC PEPTIDE INHIBITOR RECEPTOR BIND PROTEIN (GIPR) IN ASSOCIATION WITH GLP-1 AGONISTS
AU2018288852B2 (en) 2017-06-21 2025-02-27 Amgen Inc. Method of treating or ameliorating metabolic disorders using antagonistic binding proteins for gastric inhibitory peptide receptor (GIPR)/GLP-1 receptor agonist fusion proteins
MA46990B1 (en) 2017-08-24 2024-03-29 Novo Nordisk As GLP-1 COMPOSITIONS AND ITS USES
EP3728303A1 (en) 2017-12-19 2020-10-28 Novo Nordisk A/S Solubility of glp-1 peptide
WO2019200594A1 (en) * 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
TW202535454A (en) 2020-02-18 2025-09-16 丹麥商諾佛 儂迪克股份有限公司 Pharmaceutical formulations
US20240374690A1 (en) 2021-01-25 2024-11-14 Mylan Ireland Limited Pharmaceutical Peptide Compositions and Methods of Preparation Thereof
WO2022266927A1 (en) * 2021-06-24 2022-12-29 深圳翰宇药业股份有限公司 Liraglutide variant, preparation method therefor, and application thereof
WO2024166998A1 (en) 2023-02-09 2024-08-15 三井化学株式会社 Method for producing magnesium compound particles, method for controlling olefin polymer particle shape, olefin polymer particles

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3419824A1 (en) * 1984-05-26 1985-11-28 Bayer Ag, 5090 Leverkusen METHOD AND MOLDING TOOL FOR PRODUCING MOLDED PARTS WITH GRILL, GRID OR RUST-LIKE AREAS, LIKE VEHICLE SOFT FACES, SPOILERS, BUMPER, FROM A FLOWABLE DIMENSION
HU225496B1 (en) * 1993-04-07 2007-01-29 Scios Inc Pharmaceutical compositions of prolonged delivery, containing peptides
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
ATE269103T1 (en) * 1998-03-13 2004-07-15 Novo Nordisk As STABILIZED AQUEOUS GLUCAGON SOLUTIONS CONTAINING DETERGENTS
US6844321B2 (en) * 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue

Also Published As

Publication number Publication date
BR0107837A (en) 2003-01-14
MXPA02007231A (en) 2002-12-09
US20130072658A1 (en) 2013-03-21
JP2003523366A (en) 2003-08-05
DK1257577T3 (en) 2004-08-02
US20120101034A9 (en) 2012-04-26
US8455433B2 (en) 2013-06-04
HUP0204281A2 (en) 2003-04-28
WO2001055213A3 (en) 2002-02-28
ATE264870T1 (en) 2004-05-15
US7598222B2 (en) 2009-10-06
IL150913A0 (en) 2003-02-12
ES2218381T3 (en) 2004-11-16
US8268780B2 (en) 2012-09-18
IL189371A0 (en) 2008-06-05
KR20020073184A (en) 2002-09-19
HUP0204281A3 (en) 2007-03-28
US20120208980A1 (en) 2012-08-16
CA2396920A1 (en) 2001-08-02
PT1257577E (en) 2004-08-31
EP1257577B1 (en) 2004-04-21
US20110053838A1 (en) 2011-03-03
EP1257577A2 (en) 2002-11-20
DE60102899T2 (en) 2005-03-31
WO2001055213A2 (en) 2001-08-02
TR200401142T4 (en) 2004-07-21
US8222205B2 (en) 2012-07-17
US20030060412A1 (en) 2003-03-27
DE60102899D1 (en) 2004-05-27

Similar Documents

Publication Publication Date Title
AU2001232735A1 (en) Process for solubilizing glucagon-like peptide 1 compounds
EP2272825A3 (en) N-Protected amino hydroxy adamantane carboxylic acid and process for its preparation
AU2093100A (en) Recovery of a protein at high ph
ATE246702T1 (en) METHOD FOR PREPARING OLIGONUCLEOTIDES
CA2372339A1 (en) Pharmaceutical product comprising the active substance diamorphine, and its use in a process for treating opiate addiction
MXPA03000510A (en) Stable salts of o-acetylsalicyclic with basic amino acids.
DE69030100D1 (en) PEPTIDE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF AND THE PHARMACEUTICAL COMPOSITION CONTAINING IT
WO2002051979A3 (en) Method to remove citrate and aluminum from proteins
EP1291356A3 (en) Process for rapid solution synthesis of petides
DK1150999T3 (en) Cyclosporin derivatives and process for their preparation
EP0296581A3 (en) Amino acid 1,2-diketo derivatives as renin inhibitors
ATE322891T1 (en) DRUG DELIVERY SYSTEM FOR WATER-SOLUBLE DRUGS
AR009582A1 (en) PREPARATION PROCEDURE OF A MEDICINAL PRODUCT CONTAINING PLASMA PROTEIN FROM CITRATED PLASMA OR FROM A FRACTION OF PLASMAQUE CONTAINS CITRATE
IT1319674B1 (en) PROCESS FOR THE PREPARATION OF CYCLOHEXANACETIC ACID1- (AMINOMETHYL).
MXPA01011955A (en) Fused polycyclic amino acids as pharmaceutical agents.
MXPA03008837A (en) A stable pharmaceutical composition of pravastatin.
EP1074539A3 (en) Process for producing optically active 3,3,3,-trifluoro-2-hydroxy-2-methylpropionic acid, and salt thereof
MY119965A (en) Process for preparing methylene bisphosphonic acids and salts thereof.
IL141284A0 (en) Process for the production of n-protected azetidine-2-carboxylic acids (azeohs)
EP1065199A3 (en) "Process for the recovery of strong acids from aqueous solution"
WO2002060866A3 (en) Preparation of pure 3-alkoxymethyl cephalosporins.
MXPA05006279A (en) Process for the preparation of pregnanes.
DE60105216D1 (en) Process for the preparation of aromatic acylthiocarboxylic acid derivatives
BG103923A (en) Sulphate salt of hiv protease inhibitor with improved peroral absorption and biopresence
AU1987000A (en) Method for preparing an aza-macrolide with 4'' (r) nh2